Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy: Cardiovascular mortality
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy Cardiovascular mortality · people at increased risk of developing T2DM The review found no eligible studies for this question. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people… (2020) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of… 2020 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.